Belite Bio (BLTE) Liabilities and Shareholders Equity (2021 - 2025)

Belite Bio has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $780.6 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 413.08% year-over-year to $780.6 million; the trailing twelve-month figure through Dec 2025 stood at $1.1 billion (up 246.35% YoY), and the FY2025 full-year result was $780.6 million, up 413.08% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $780.6 million, up from $152.1 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $780.6 million in Q4 2025, with the low at $18.3 million in Q4 2021.
• Average Liabilities and Shareholders Equity over 5 years is $218.0 million, with a median of $94.6 million recorded in 2023.
• Year-over-year, Liabilities and Shareholders Equity surged 60.74% in 2024 and jumped 413.08% in 2025.
• Tracing BLTE's Liabilities and Shareholders Equity over 5 years: stood at $18.3 million in 2021, then jumped by 141.3% to $44.3 million in 2022, then soared by 113.77% to $94.6 million in 2023, then surged by 60.74% to $152.1 million in 2024, then jumped by 413.08% to $780.6 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $780.6 million (Q4 2025), $152.1 million (Q4 2024), and $94.6 million (Q4 2023), per Business Quant data.

Peer Comparison